Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435913 | 0.84 | NLRP3 (0.45) | CYP2C19CYP2C9HTTALDH1A1TSHR | |
| SCHEMBL28036323 | 0.83 | CYP2C19 (0.52) | CYP2C19CYP2C9HTTALDH1A1CYP3A4 | |
| SCHEMBL8770955 | 0.83 | CYP2C19 (0.52) | CYP2C19CYP2C9HTTALDH1A1CYP3A4 | |
| SCHEMBL12290669 | 0.81 | NR3C2 (0.42) | CYP2C19CYP2C9HTTALDH1A1KDM4E | |
| SCHEMBL17754986 | 0.81 | HTT (0.51) | HTTALDH1A1KMT2AKCNA5MAPT | |
| SCHEMBL31296529 | 0.81 | HTT (0.49) | CYP2C19CYP2C9HTTALDH1A1CYP3A4 | |
| SCHEMBL1613850 | 0.81 | HTT (0.49) | CYP2C19CYP2C9HTTALDH1A1CYP3A4 | |
| SCHEMBL31626979 | 0.80 | CYP2C9 (0.50) | CYP2C19CYP2C9HTTALDH1A1TSHR | |
| SCHEMBL17749159 | 0.80 | ADRB2 (0.45) | ALDH1A1KCNA5MAPTRAB9ALMNA | |
| SCHEMBL26455960 | 0.80 | MEN1 (0.48) | CYP2C19CYP2C9ALDH1A1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289793-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4519251-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | Esperion Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023215220-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2016077240-A2 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | CYP2C19 4784/4885CYP2C9 4795/4885HTT 3200/4885 |
| US-20250289793-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ACLY, CS, ATP5ME | CYP2C19 980/4885CYP2C9 887/4885HTT 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.